Teleflex’s second quarter was marked by revenue and non-GAAP earnings per share above Wall Street expectations, yet the operating margin declined significantly year over year. Management attributed the quarter’s results primarily to strong execution in its Vascular and Surgical businesses, as well as accelerated progress on its strategic transformation plan. CEO Jason Weidman cited robust demand for hemostatic and ligation products but acknowledged that performance in the Interventional segment lagged due to ongoing integration and restructuring activities related to the VI acquisition.
Is now the time to buy TFX? Find out in our full research report (it’s free for active Edge members).
Teleflex (TFX) Q2 CY2026 Highlights:
- Revenue: $570.3 million vs analyst estimates of $559.1 million (28.9% year-on-year growth, 2% beat)
- Adjusted EPS: $1.76 vs analyst estimates of $1.28 (37.4% beat)
- Management raised its full-year Adjusted EPS guidance to $7.05 at the midpoint, a 10.2% increase
- Operating Margin: 12.8%, down from 20.6% in the same quarter last year
- Constant Currency Revenue rose 4.7% year on year (1% in the same quarter last year)
- Market Capitalization: $5.78 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Teleflex’s Q2 Earnings Call
- Jayson Bedford (Raymond James & Associates) asked about the new CEO’s comfort with the current strategy and any early concerns. CEO Jason Weidman responded that he remains confident in the transformation plan and is conducting a comprehensive business review for long-term planning.
- Jayson Bedford (Raymond James & Associates) also pressed for specifics on the Interventional integration delays. Weidman detailed that order-to-cash, distributor, and sales force transitions were the primary causes, but emphasized these are being actively addressed.
- Patrick Wood (UBS) sought clarity on the more conservative second half outlook and whether midterm growth above 4% is realistic. Weidman stated that the guidance reduction is solely due to Interventional integration delays, not broader market or procedural headwinds.
- Michael Matson (Needham & Company) asked about the EZPLAZ launch timeline and market size. Weidman confirmed that 2026 revenue impact will be minimal, with government and military channels the initial focus, and a reassessment of total market opportunity underway.
- Nathan Treybeck (Wells Fargo) questioned the impact of regulatory changes on Freesolve pricing and adoption. Weidman acknowledged the loss of the NTAP shortcut but stressed that clinical trial success could still support long-term potential regardless of reimbursement pathway.
Catalysts in Upcoming Quarters
Looking ahead, our team will be monitoring (1) the pace of resolving integration and sales force challenges in the Interventional business, (2) the closing of the Acute Care and Interventional Urology divestitures and deployment of proceeds, and (3) initial commercialization steps and contract wins for EZPLAZ in the U.S. government and military segment. Progress on the Freesolve clinical program and execution of restructuring cost savings will also be important to track.
Teleflex currently trades at $137.00, in line with $136.78 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.